header-9.jpg
Translational Research

Translational Research

The Australian Prostate Cancer Research Centre – Queensland (APCRC–Q) seamlessly spans the spectrum of prostate cancer research – that is, discovery, prognostic biomarker and therapeutic development – through the expertise and passion of a large, coordinated, multidisciplinary research team, underpinned by leading technology. This critical mass of diverse expertise is leveraged extensively by existing physical infrastructure, capital development, national and international peer-reviewed funding, engaging with biotechnology, pharmaceutical and other industries and relevant government agencies.

The Centre’s specific research goals involve developing new therapeutic strategies for advanced disease, with an emphasis on rationalised combination strategies with androgen targeted agents and prostate cancer progression pathways. In stride with therapeutic goals the APCRC-Q seeks to identify, validate and develop biomarkers for genetic predisposition, prognostication to differentiate indolent from aggressive disease, therapeutic response indicators to inform treatment options and planning. To effect these developments into clinical management the APCRC-Q engages in health services and health economics research with an aim to define current prostate cancer patterns of practice across the prostate cancer patient journey and use this information and models to optimize care with appropriate interventions.

APCRC-Q's research activities across the spectrum of translational research are categorised into Discovery, Pre-Clinical, Clinical Trials and Health Services